Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mol Cancer Res. 2013 Feb 5;11(5):494–505. doi: 10.1158/1541-7786.MCR-12-0528

Figure 7. Signaling schematic illustrating the effects of JSI-124 treatment in GBM cells.

Figure 7

JSI-124 treatment activates the NF-κB pathway by phosphorylation (P) of NF-κB p65 protein, subsequent nuclear localization and IκBα degradation (Ub, ubiquitin). Once in the nucleus, phosphorylated NF-κB dimers bind to the promoters of IL-6, IL-8 and SOCS3 and begin gene transcription. IL-6 and IL-8 mRNA are translated into protein and secreted into the medium. SOCS3 mRNA is also translated into protein and acts as a negative regulator of JAK/STAT3, preventing STAT3 activation.